SOLNET-GROUP
Solnet Group, a leading provider of smart solar energy solutions for commerce and industry, has released a new report addressing the critical issue of safety in rooftop solar installations. Titled "Safety and Security in C&I Rooftop PV,” the white paper outlines the most important considerations rooftop solar owners and installers can take to minimize risk and protect their investments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240115915852/en/
High-quality installers and components reduce risks later (Photo: Business Wire)
According to an audit by Clean Energy Associates, 97% of rooftop solar installations have major safety concerns. Solar panels that are improperly installed or maintained contribute not only to physical safety hazards such as fires but also to power outages and financial losses. A thorough understanding of these risks is necessary as more companies install rooftop solar to mitigate high energy costs and comply with new regulations. Against this backdrop, Solnet Group has compiled a review of risk-reducing technologies and best practices, focusing on how safety can impact the bottom line.
Safety in solar is highly relevant
The revised European Union’s Energy Performance of Buildings Directive will require rooftop solar on all new commercial buildings by 2026, and in renovated commercial buildings by 2027. Beyond this, up to 28% of European companies plan to voluntarily install a solar system within the next 3 years. With rapid growth in the number of solar installations, the risks grow as well. For businesses entering this market, a balance must also be found between upfront installation costs and the long-term operational costs of the array. By considering safety measures from the outset, companies can reduce both risks and costs by minimizing performance issues, keeping insurance premiums low, and mitigating disruptions.
Key findings
1. Safety is a prerequisite for investor confidence: A proactive approach to reducing risk enhances the lifespan of the array and ensures consistent energy generation. In turn, the project generates more value over its lifetime, creating assurance that rooftop solar systems are a viable investment.
2. High-quality installers and components reduce risks later: Comprehensive analyses of solar panel fires from both Germany and the UK indicate that installer error is one of the leading causes of fire incidents, illustrating the importance of a careful installation process. The right components can also mitigate fire risks and other hazards from electrical arcs. Power optimizers, which enable the panel field to be made voltage-free to facilitate firefighting and rescue operations, are increasingly required by insurers as a safety measure in solar installations.
3. Smart monitoring and maintenance tools contribute to a higher safety standard: Real-time monitoring and data analysis tools, coupled with automatic rapid shutdown, allow threats to be addressed right away. As a result, damage is minimized or even avoided, and the operator has a clearer overview of how the system is functioning. The international Zurich Insurance company has recently recommended smart solar systems in part due to the features of their panel-level power optimizers, which can be operated through remote control.
"The rationale behind Solnet’s focus on smart solar technology is not just efficiency; it's about ensuring our solar systems' quality, safety, and longevity. By incorporating features like continuous monitoring and protection mechanisms, we are elevating the safety standards of rooftop solar installations. Our report sheds light on the role of safety improvements in protecting investments and furthering the energy transition," says Arttur Kulvik, SVP Business Development at Solnet Group.
Solnet Group prioritizes safety in every stage of the design, installation, operations, and maintenance of its solar arrays. The company includes power optimizers and a suite of remote monitoring tools, including immediate fault detection alerts, as standard features in its smart solar systems.
The full report is available for download here. Solnet Group will also host a webinar on safety in commercial and industrial rooftop PV, together with representatives from SolarEdge and Zurich Insurance. Registration is open until January 18th.
The speakers at this webinar include Georg Stockschläder, RE Global Practice Leader Property at Zurich Insurance; Chris Voet, Key Accounts Director at Solar Edge; and Arttur Kulvik, SVP Business Development at Solnet Group.
About Solnet Group:
Established in 2014, Solnet Group is a rapidly growing solar energy company with units in the Netherlands, Germany, and Finland. In 2020, the company was listed as the 59th fastest-growing company in Europe on the Financial Times FT1000 list and ranked third in the energy sector. As early as 2016, Solnet Group received the Climate Solver award from WWF. Solnet Group offers comprehensive and high-quality services from consulting and planning to installation throughout Europe. To facilitate our clients' projects, we also provide services for project financing, solar plant maintenance, and repairs. Solnet Group's clientele includes major investment funds, shopping centers, retailers, as well as storage and logistics companies. For more information, visit www.solnet.group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240115915852/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom